Dyadic International (NASDAQ:DYAI) Stock Passes Below Fifty Day Moving Average – Here’s What Happened

Dyadic International Inc. (NASDAQ:DYAI)’s share price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.79 and traded as low as $0.6870. Dyadic International shares last traded at $0.7106, with a volume of 79,647 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Price Performance

The stock has a market capitalization of $25.89 million, a PE ratio of -3.09 and a beta of 1.17. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The company’s 50 day simple moving average is $0.79 and its 200 day simple moving average is $0.85.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. On average, equities analysts anticipate that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Institutional Trading of Dyadic International

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Marathon Capital Management boosted its position in Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 50,000 shares during the period. Apis Capital Advisors LLC purchased a new stake in Dyadic International during the 3rd quarter worth $1,817,000. Landscape Capital Management L.L.C. acquired a new position in Dyadic International in the 3rd quarter worth $190,000. Finally, Truist Financial Corp lifted its holdings in Dyadic International by 30.5% in the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after buying an additional 76,200 shares in the last quarter. 27.95% of the stock is owned by hedge funds and other institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.